Source comparison
Comparison: BPC-157 Protocol by Age Bracket
| Age Bracket | Dosage per Injection | Frequency | Total Daily Dose | Cycle Length | Primary Rationale | Professional Assessment ||—|—|—|—|—|—|| 20–29 | 250–500mcg | Once daily (pre-sleep) | 250–500mcg | 4–6 weeks | Peak endogenous GH and collagen synthesis ra
This comparison does not assign a generated winner or score.
- | Age Bracket | Dosage per Injection | Frequency | Total Daily Dose | Cycle Length | Primary Rationale | Professional Assessment ||—|—|—|—|—|—|| 20–29 | 250–500mcg | Once daily (pre-sleep) | 250–500mcg | 4–6 weeks | Peak endogenous GH and collagen synthesis rates support single-dose efficacy | Optimal for most injury types; no adjustments needed || 30–39 (bpc-157 30s age specific protocol) | 200–300mcg | Twice daily (pre-sleep + mid-morning) | 400–600mcg | 6–8 weeks | Compensates for declining GH pulses and reduced collagen synthesis baseline | Recommended for connective tissue injuries; acute injuries may resolve faster || 40–49 | 250–350mcg | Twice daily (pre-sleep + mid-morning) | 500–700mcg | 8–10 weeks | Further GH decline and slower tissue remodeling require extended exposure | Higher total dose compensates for reduced anabolic capacity || 50+ | 300–400mcg | Twice daily (pre-sleep + mid-morning) | 600–800mcg | 10–12 weeks | Severe GH suppression and collagen deficit require maxim